These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 11213905)

  • 1. Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes.
    Moriyama H; Nagata M; Fujihira K; Yamada K; Chowdhury SA; Chakrabarty S; Jin Z; Yasuda H; Ueda H; Yokono K
    Diabetes Care; 2001 Feb; 24(2):411-2. PubMed ID: 11213905
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of insulin allergy in a 1-year-old infant with neonatal diabetes by lispro and glargine insulin.
    Kara C; Kutlu AO; Evliyaoglu O; Bilgili H; Yildirim N
    Diabetes Care; 2005 Apr; 28(4):983-4. PubMed ID: 15793215
    [No Abstract]   [Full Text] [Related]  

  • 3. Insulin glargine (HOE901): first responsibilities: understanding the data and ensuring safety.
    Buse J
    Diabetes Care; 2000 May; 23(5):576-8. PubMed ID: 10834411
    [No Abstract]   [Full Text] [Related]  

  • 4. Desensitization of allergy to human insulin and its analogs by administering insulin aspart and insulin glargine.
    Wu P; Ji C; Wang M; Zou S; Ge W
    Ann Endocrinol (Paris); 2013 Feb; 74(1):56-8. PubMed ID: 23351561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Insulin allergy whose local/systemic reactions were reduced by desensitization with long-acting insulin analog, glargine].
    Tuboi M; Tsuchiya T; Taguchi R; Tanaka Y; Iwasaki Y; Hashimoto K; Kakizaki S; Okada S; Shimizu H; Mori M
    Nihon Naika Gakkai Zasshi; 2010 Jan; 99(1):133-5. PubMed ID: 20196485
    [No Abstract]   [Full Text] [Related]  

  • 6. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells.
    Bähr M; Kolter T; Seipke G; Eckel J
    Eur J Pharmacol; 1997 Feb; 320(2-3):259-65. PubMed ID: 9059862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glargine insulin is not an alternative in insulin allergy.
    Durand-Gonzalez KN; Guillausseau N; Pecquet C; Gayno JP
    Diabetes Care; 2003 Jul; 26(7):2216. PubMed ID: 12832347
    [No Abstract]   [Full Text] [Related]  

  • 8. Insulin glargine.
    Am J Health Syst Pharm; 2000 Nov; 57(21):1960-1. PubMed ID: 11094649
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimizing glycemic control with insulin glargine.
    Williams JB
    Diabetes Technol Ther; 2003; 5(3):471-3. PubMed ID: 12828834
    [No Abstract]   [Full Text] [Related]  

  • 10. Insulin glargine: a new basal insulin analogue.
    Younis N; Soran H; Bowen-Jones D
    QJM; 2002 Nov; 95(11):757-61. PubMed ID: 12391389
    [No Abstract]   [Full Text] [Related]  

  • 11. Reducing mistakes in patient administration of glargine and lispro.
    Schutta MH
    Diabetes Care; 2002 Jun; 25(6):1098-9. PubMed ID: 12032124
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes.
    Schober E; Schoenle E; Van Dyk J; Wernicke-Panten K;
    Diabetes Care; 2001 Nov; 24(11):2005-6. PubMed ID: 11679478
    [No Abstract]   [Full Text] [Related]  

  • 13. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
    Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
    Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of insulin glargine during pregnancy in a type 1 diabetic woman.
    Devlin JT; Hothersall L; Wilkis JL
    Diabetes Care; 2002 Jun; 25(6):1095-6. PubMed ID: 12032121
    [No Abstract]   [Full Text] [Related]  

  • 15. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting insulin analogs versus human insulins.
    Garg SK; Naik RG
    Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
    [No Abstract]   [Full Text] [Related]  

  • 17. Comment on: Distiller LA, Joffe BI (2006) From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic? Diabetologia 49:2793-2794.
    Bell DS
    Diabetologia; 2007 Mar; 50(3):695. PubMed ID: 17235522
    [No Abstract]   [Full Text] [Related]  

  • 18. [Flexible intensive insulin therapy: a change in mentalities].
    Penfornis A; Chabroux S; Grimaldi A
    Rev Med Interne; 2008 Nov; 29(11):857-60. PubMed ID: 18387717
    [No Abstract]   [Full Text] [Related]  

  • 19. From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic?
    Distiller LA; Joffe BI
    Diabetologia; 2006 Nov; 49(11):2793-4. PubMed ID: 17047914
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.